FDA, CMS Parallel Review Pilot Opens Opportunities for Personalized Medicine Molecular Dx
October 12, 2011
FDA, CMS Parallel Review Pilot Opens Opportunities for Personalized Medicine Molecular Dx
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- With Top-line Deep-C Trial Data, Exact Sciences Gears Up for FDA and CMS Submissions for Cologuard
April 24, 2013 / Pharmacogenomics Reporter - Exact Sciences Discusses Benefits of Taking Cologuard through FDA/CMS Parallel Review Pilot
April 3, 2013 / Pharmacogenomics Reporter - FDA/CMS Parallel Review of Medical Products Limited Only by Sponsors' Reluctance, CMS Official Says
December 7, 2011 / Pharmacogenomics Reporter - Q&A: ACLA President Alan Mertz Discusses Citizen Petition Against FDA Regulation of LDTs
June 12, 2013 / Pharmacogenomics Reporter - CMS Issues Pricing for MDx Codes; Labs, Test Developers Still Critical of Rates and Methodology
May 22, 2013 / Pharmacogenomics Reporter